Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)
 
 • Company Description   
Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

Number of Employees: 141

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.79 Daily Weekly Monthly
20 Day Moving Average: 982,427 shares
Shares Outstanding: 51.72 (millions)
Market Capitalization: $765.00 (millions)
Beta: 2.20
52 Week High: $69.12
52 Week Low: $13.64
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -56.35% -52.20%
12 Week -63.09% -58.52%
Year To Date -76.71% -71.54%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 Arsenal Yards Blvd. Suite 230
-
Watertown,MA 02472
USA
ph: 857-285-5300
fax: -
investors@kymeratx.com http://www.kymeratx.com
 
 • General Corporate Information   
Officers
Nello Mainolfi - Chief Executive Officer and Presdent
Bruce Booth - Chairman
Bruce Jacobs - Chief Financial Officer
Jeff Albers - Director
Pamela Esposito - Director

Peer Information
Kymera Therapeutics, Inc. (CORR.)
Kymera Therapeutics, Inc. (RSPI)
Kymera Therapeutics, Inc. (CGXP)
Kymera Therapeutics, Inc. (BGEN)
Kymera Therapeutics, Inc. (GTBP)
Kymera Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 501575104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 51.72
Most Recent Split Date: (:1)
Beta: 2.20
Market Capitalization: $765.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 5.20% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.78
Price/Cash Flow: -
Price / Sales: 12.00
EPS Growth
vs. Year Ago Period: -144.83%
vs. Previous Quarter: -7.58%
Sales Growth
vs. Year Ago Period: -48.55%
vs. Previous Quarter: -37.01%
ROE
03/31/22 - -30.40
12/31/21 - -27.16
09/30/21 - -24.30
ROA
03/31/22 - -22.06
12/31/21 - -18.67
09/30/21 - -15.58
Current Ratio
03/31/22 - 4.88
12/31/21 - 4.88
09/30/21 - 5.75
Quick Ratio
03/31/22 - 4.88
12/31/21 - 4.88
09/30/21 - 5.75
Operating Margin
03/31/22 - -194.23
12/31/21 - -137.60
09/30/21 - -112.31
Net Margin
03/31/22 - -194.23
12/31/21 - -137.60
09/30/21 - -112.31
Pre-Tax Margin
03/31/22 - -194.23
12/31/21 - -137.60
09/30/21 - -112.31
Book Value
03/31/22 - 8.29
12/31/21 - 8.94
09/30/21 - 9.40
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.22
12/31/21 - 0.25
09/30/21 - 0.28
 

Powered by Zacks Investment Research ©